Price$17.00-0.16 (-0.90%)
01:30 PM07:45 PM
News · 26 weeks41+400%
2025-11-092026-05-03
Mix3390d
- SEC Filings14(42%)
- Insider11(33%)
- Other5(15%)
- Earnings2(6%)
- Offering1(3%)
Latest news
25 items- SECSEC Form FWP filed by Viridian Therapeutics Inc.FWP - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
- SECSEC Form FWP filed by Viridian Therapeutics Inc.FWP - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
- SECSEC Form 305B2 filed by Viridian Therapeutics Inc.305B2 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- PRViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 MillionViridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the "Convertible Notes" and such offering, the "Convertible Notes Offering") and its upsized underwritten public offering of 7,352,942 shares of its common stock at a public offering price of $17.00 per share (such offering, the "Equity Offering"). Viridian estimates that the aggregate net proceeds from the Convertible Notes Offering and th
- SECSEC Form 424B5 filed by Viridian Therapeutics Inc.424B5 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- SECSEC Form 424B5 filed by Viridian Therapeutics Inc.424B5 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- SECSEC Form FWP filed by Viridian Therapeutics Inc.FWP - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
- PRViridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred StockViridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced that it has commenced underwritten public offerings of $150.0 million aggregate principal amount of convertible senior notes due 2032 (the "Convertible Notes" and such offering, the "Convertible Notes Offering") and $100.0 million of shares of its common stock and, in lieu of common stock to certain investors, shares of its Series B non-voting convertible preferred stock (the "Equity Offering"). In addition, Viridian intends to grant the underwriters of the Convertible Notes Offering a
- SECViridian Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- SECSEC Form 10-Q filed by Viridian Therapeutics Inc.10-Q - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- SECViridian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- PRViridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress- PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease (TED); organization is launch-ready - - Marketing Authorization Application (MAA) for veligrotug in TED submitted to the European Medicines Agency (EMA) in January 2026 and accepted for review in February 2026 - - Subcutaneous elegrobart showed positive topline data in REVEAL-1 and REVEAL-2 phase 3 clinical trials in active and chronic TED, respectively; Biologics License Application (BLA) submission anticipated in Q1 2027 with the potential to be the first subcutaneous autoinjector treatment for TED - - FcRn portfolio on track to share VRDN-006 development plan in 2026, and for VRDN-008 phase 1 healthy
- PRViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease- REVEAL-2 met its primary endpoint with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved 50% and 54% proptosis responder rates (PRR) at week 24, respectively, versus 15% placebo, both highly statistically significant results (p < 0.0001) - - Elegrobart Q4W achieved a statistically significant 61% diplopia responder rate at week 24, versus 38% placebo (p = 0.0118) - - Elegrobart was generally well tolerated in both dose groups, with a safety profile consistent with REVEAL‑1 and low rates of hearing impairment - - Elegrobart is the only subcutaneous program to demonstrate positive phase 3 data in both active and chronic TED pivotal clinical tria
- SECSEC Form DEFA14A filed by Viridian Therapeutics Inc.DEFA14A - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- SECSEC Form DEF 14A filed by Viridian Therapeutics Inc.DEF 14A - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- SECViridian Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- PRViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease- REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18% placebo at week 24 - - Complete resolution of diplopia in 51% of patients treated Q4W versus 16% placebo at week 24 - - Elegrobart was generally well tolerated in both dose groups with low rates of hearing impairment - - REVEAL-2, a phase 3 clinical trial evaluating elegrobart in patients with chronic TED, is on track for topline readout in Q2 2026; BLA submission anticipated in Q1 2027 - - Viridian ended Q4 2025 with $875 million in cash; the company anticipates exist
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Viridian Therapeutics Inc.SCHEDULE 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
- INSIDERAmendment: Chief Financial Officer Harmon Seth covered exercise/tax liability with 2,031 shares, decreasing direct ownership by 21% to 7,850 units (SEC Form 4)4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERAmendment: Chief Operating Officer Beetham Thomas W. covered exercise/tax liability with 3,048 shares, decreasing direct ownership by 19% to 13,361 units (SEC Form 4)4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERAmendment: Chief Legal Officer Tousignant Jennifer covered exercise/tax liability with 1,675 shares, decreasing direct ownership by 32% to 3,494 units (SEC Form 4)4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERAmendment: President and CEO Mahoney Stephen F. covered exercise/tax liability with 7,408 shares, decreasing direct ownership by 18% to 33,349 units (SEC Form 4)4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERChief Legal Officer Tousignant Jennifer converted options into 5,169 shares and covered exercise/tax liability with 1,724 shares (SEC Form 4)4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERChief Financial Officer Harmon Seth covered exercise/tax liability with 2,091 shares and converted options into 6,267 shares, increasing direct ownership by 116% to 7,790 units (SEC Form 4)4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Financial Officer Harmon Seth4/A - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
VRDN FAQ
7 questionsWhat does Viridian Therapeutics Inc. do?
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.Where does VRDN stock trade?
Viridian Therapeutics Inc. (VRDN) is listed on NASDAQ.What sector and industry is VRDN in?
Viridian Therapeutics Inc. operates in the Health Care sector, Medical Specialities industry.When did Viridian Therapeutics Inc. go public?
Viridian Therapeutics Inc. (VRDN) completed its IPO in 2014.What are analysts saying about VRDN?
Viridian Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wedbush: Outperform with a $4700.00 price target on 2025-12-10. Recent price targets range from $2700.00 to $4700.00.What companies are similar to VRDN?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare VRDN side-by-side with any of them on Quantisnow.How can I track VRDN on Quantisnow?
Quantisnow aggregates Viridian Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VRDN to receive live email and push alerts on every new disclosure.